Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Equip Capital and Remagruppen in connection with the acquisition of Beredningsbart Syd
Mandate

Vinge advises Equip Capital and Remagruppen in connection with the acquisition of Beredningsbart Syd

October 23, 2023 Employment and Benefits M&A Real Estate and Construction

Vinge has advised the Norwegian private equity firm Equip Capital and its portfolio company Remagruppen in connection with the acquisition of Beredningsbart Syd AB (”BNB Syd”).

BNB Syd provides qualitative services within decontamination, demolition, recessing and waste management and conducts operations in southern Sweden. Remagruppen acquires and develops well-managed, stable and entrepreneur managed companies within the field of sustainable property maintenance.

Vinge’s team primarily consisted of Karl Klackenberg, Carl Fredrik Wachtmeister and Maximillian Bengtsson (M&A), Clara Klingspor (Construction), Olivia Onwuta (Employment) and Emma Emsjö (Project Assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025